From AI diagnostics to exoskeletons, the event highlights how healthcare tech is moving into real-world use
Updated
April 8, 2026 10:43 AM
Tesla Bot Optimus, designed by Tesla. PHOTO: ADOBE STOCK
The China International Medical Equipment Fair 2026 will open in Shanghai from April 9 to 12 at the National Exhibition and Convention Center. It is one of the largest gatherings in the medical device industry. This year’s edition will cover more than 320,000 square metres. Nearly 5,000 companies and brands are expected to participate, representing over 20 countries and regions. Organisers also expect more than 200,000 professional visitors and buyers from around 150 markets.
A key focus this year is the growing use of artificial intelligence in healthcare. One of the headline technologies is an AI agent designed to carry out multiple diagnoses from a single scan. The exhibition will also feature diagnostic software that is already in clinical use. In addition, an integrated platform for AI training and inference will be showcased to improve computing capacity within healthcare institutions.
Robotics will also play a central role at the event. New systems across surgical procedures, rehabilitation and elderly care are expected to be presented. Together, these developments point to a steady move toward more precise and assisted forms of care. Many of these technologies are designed to support clinicians and patients, especially in tasks that require consistent accuracy or long-term physical assistance.
For the first time, the event will introduce a dedicated Future Tech Arena. It will focus on brain-computer interfaces, embodied intelligence and university-led innovation. The space will include AI-assisted MRI systems for Alzheimer’s diagnosis. It will also feature brain-computer interface technologies used for cognitive assessment and training, along with wearable robotic exoskeletons.
Alongside product showcases, the event will continue to act as a platform for international trade and collaboration. An International Zone will host exhibitors from countries such as the United States, Germany, Japan, South Korea, the United Kingdom, France, Singapore, Malaysia and Thailand. This provides a view of how different markets are approaching medical technology. It also reflects the global nature of innovation and deployment in this sector.
The programme will include a set of networking and exchange formats under its “We” initiative. These include discussion stages with representatives from consulates and industry organisations, as well as matchmaking sessions based on verified buyer demand. Guided tours will also be organised to help international visitors connect with relevant exhibitors. In parallel, organisers are working with hospital partners to provide medical support services for attendees during the event.
Across the four days, hundreds of forums are scheduled. These will bring together policymakers, researchers and industry leaders to discuss regulatory frameworks, market access and the future of healthcare innovation. Some of these sessions will be led by the Global Harmonization Working Party in collaboration with the Ministry of Health of Malaysia, with a focus on regulatory alignment and cross-border cooperation in medical devices.
As healthcare systems continue to adopt digital tools and advanced equipment, events like CMEF provide a clear view of how these technologies are being developed and applied. The scale of participation this year reflects continued activity across both innovation and international collaboration in the medical device sector.
Keep Reading
Humanoids are moving from research labs into real industries — and capital is finally catching up.
Updated
January 8, 2026 6:31 PM
A face of a humanoid robot, side view on black background. PHOTO: UNSPLASH
Humanoid robots are shifting from sci-fi speculation to engineering reality, and the pace of progress is prompting investors to reassess how the next decade of physical automation will unfold. ALM Ventures has launched a new US$100 million early-stage fund aimed squarely at this moment—one where advances in robot control, embodied AI and spatial intelligence are beginning to converge into something commercially meaningful.
ALM Ventures Fund I, is designed for the earliest stages of company formation, targeting seed and pre-seed teams building the foundations of humanoid deployment. It’s a concentrated fund that seeks to take early ownership in a sector that many now consider the next major technological frontier.
For Founder and General Partner Modar Alaoui, the timing is not accidental. “After years of research, humanoids are finally entering a phase where performance, reliability and cost are converging toward commercial viability”, he said. “What the category needs now is focused capital and deep technical diligence to turn prototypes into scalable, enduring companies”.
That framing captures a shift happening across robotics: the field is moving out of the lab and into early commercial readiness. Improvements in perception systems, model-based reasoning and motion control are accelerating the transition. Advances in simulation are also lowering the complexity and cost of integrating humanoid platforms into real environments. As these systems become more capable, the gap between research prototypes and market-ready products is narrowing.
ALM Ventures is positioning itself at this inflection point. Fund I’s thesis centers on the core technologies required to scale humanoids safely and economically. This includes next-generation robot platforms, spatial reasoning engines, embodied intelligence models, world-modeling systems and the infrastructure needed for early deployment. Rather than chasing every robotics trend, the fund is concentrating on the essential layers that will determine whether humanoids can work reliably outside controlled settings.
The firm isn’t starting from zero. During the fund’s formation, ALM Ventures made ten early investments that directly align with its investment focus. The portfolio includes companies building at different layers of the humanoid stack, such as Sanctuary AI, Weave Robotics, Emancro, High Torque Robotics, MicroFactory, Mbodi, Adamo, Haptica Robotics, UMA and O-ID. The list reflects a broad but intentional spread, from hardware to intelligence to manufacturing approaches, all oriented toward enabling scalable physical AI.
Beyond capital, ALM Ventures has been shaping the ecosystem through its global Humanoids Summit series in Silicon Valley, London and Tokyo. The series gives the firm early visibility into emerging technologies, pre-incorporation teams and the senior leaders steering the global robotics landscape. That vantage point has helped the firm identify where commercialization is truly taking root and where bottlenecks still exist.
The rise of humanoids is often compared to the early days of self-driving cars: a long arc of research suddenly meeting an acceleration point. What separates this moment is that advances in embodied AI and spatial intelligence are giving robots a more intuitive understanding of the physical world, making them easier to deploy, teach and scale. ALM Ventures’ Fund I is an attempt to capture that transition while shaping the companies that could define the next technological era.
With US$100 million dedicated to the earliest builders in the space, ALM Ventures is signaling its belief that humanoids are not just another robotics cycle—they may be the next major platform shift in AI.